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Background: The efficacy and safety of 750-mg, 5-day levofloxacin was recently
shown to be comparable to 500-mg, 10-day levofloxacin in a randomized, double-
blind, multicentre clinical trial for mild-to-severe community-acquired pneumonia
(CAP). This subgroup analysis attempted to compare the safety and efficacy of a
short-course levofloxacin regimen with traditional levofloxacin dosing for PSI Class
III/IV patients.
Methods: This retrospective, subgroup analysis focused on Pneumonia Severity
Index Class III and IV patients enrolled in the study. Measurements included clinical
and microbiological success rates, adverse events, and symptom resolution by day 3
of therapy.
Results: Of the 528 patients in the ITT population, 219 (41.5%) were categorized as
PSI Class III/IV and included in this analysis. Among the clinically evaluable patients,
90.8% (69/76) of patients treated with the 750-mg regimen achieved clinical success,
compared with 85.5% (71/83) treated with 500-mg levofloxacin (95% CI,15.9 to
5.4). Eradication rates in the microbiologically evaluable population were compar-
able for the 750- and 500-mg regimens (88.9% vs 87.5%, respectively; 95% CI,18.3
to 15.6). Both regimens were well tolerated and had comparable safety profiles.
A greater proportion of patients in the 750-mg treatment group experienced
resolution of fever (48.4% vs 34.0%; P ¼.046) and purulent sputum (48.4% vs 27.5%;
P ¼.007) by day 3 of therapy.Elsevier Ltd. All rights reserved.
2998; fax: 202 291 2031.
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A.F. Shorr et al.2130Conclusions: The 750-mg, 5-day levofloxacin course achieved comparable clinical
and microbiologic efficacy to the 500-mg, 10-day regimen. By day 3 of therapy, a
greater proportion of patients in the 750-mg group had objective and subjective
resolution of fever. Further research is needed to determine the economic
significance of short-course levofloxacin therapy.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Community-acquired pneumonia (CAP) accounts for
approximately 1 million hospitalizations in the US
annually1 and results in an enormous burden to
hospitals at a time of intense economic pressure.
CAP is the leading cause of mortality due to
infectious disease, and one estimate calculated
the total annual inpatient costs in the US of $4.4
billion (in 1995 dollars) due to this disease.2 To
reduce the number of unnecessary admissions,
treatment guidelines have provided recommenda-
tions for appropriately screening patients for
hospitalization.1,3 Additionally, some hospitals have
implemented critical pathways to limit hospital
admissions and length of stay to minimize overall
healthcare costs.4 The Pneumonia Severity Index
(PSI) score developed by Fine et al. is commonly
used to identify patients at risk for death, thereby
making hospital admission decisions more evi-
dence-based.3,5,6
Short-course antibiotic therapy may provide new
means to reduce healthcare costs. Numerous
studies have investigated the practical aspects of
short-course therapy for CAP, though few have
focused on the more severely ill population.7–9 In
general, these patients are older, present with
comorbidities, may be at a greater risk of treat-
ment failure, and tend to have longer length of
stay at hospitals.10 For these reasons, hospitaliza-
tion and more aggressive antimicrobial therapy may
be necessary to achieve optimal clinical out-
comes.1,11
Higher doses of antimicrobials, such as a 750-mg
dose of levofloxacin, may allow the use of short-
course regimens without compromising clinical
outcomes. The 750-mg levofloxacin dose provides
a number of theoretical advantages for treating
these patients. As with all fluoroquinolones, levo-
floxacin exhibits concentration-dependent bacter-
icidal activity, and microbiologic eradication is
dependent on the ratio of the area under the
concentration–time curve to minimal inhibitory
concentration (AUC/MIC), or the peak concentra-
tion to MIC (Cmax/MIC).
12 Compared to the 500-mg
dose, the 750-mg dose provides approximately
double the serum AUC and Cmax values,
13,14 and invitro pharmacodynamic studies suggest more rapid
bacterial killing with the higher dose, including
effective eradication of tested strains of ciproflox-
acin-resistant Streptococcus pneumoniae.15 The
more rapid eradication may lead to earlier symp-
tom resolution as well as a decreased risk for
resistance emergence.
Recently, the 750-mg, 5-day levofloxacin regimen
was shown to achieve comparable clinical and
microbiological outcomes to those of a 500-mg
levofloxacin regimen for 10 days.16,17 Evidence also
suggested that the 750-mg dose results in more
rapid symptom resolution, particularly resolution of
fever.18 Not presented in the original study report
was an analysis of levofloxacin efficacy in the
more severely ill or bacteremic CAP patients.19
Our current report provides a subgroup analysis of
patients in the trial who belonged to PSI Class
III/IV and required hospitalization, as well as
all patients diagnosed with bacteremia. These
patients may also be more prone to tolerability
issues because of the presence of comorbidities
and reduced renal elimination. This analysis
attempts to determine if a high-dose levofloxacin
regimen can safely and effectively treat PSI
III/IV CAP patients with a short course and whether
the 750-mg dose affects the time for symptom
resolution compared to the 500-mg levofloxacin
dose.Patients and methods
Study design
This was a retrospective subgroup analysis of a
randomized, double-blind, active-treatment-con-
trolled, noninferiority study. The study design has
been previously described.17 Briefly, adult (X18
years old) men and women with a diagnosis of mild-
to-severe CAP were eligible for enrolment. For this
analysis, only those patients that belonged to PSI
Class III (Score 470 but p90) or PSI Class IV (490
but p130) were included.3 Five patients in the
intent-to-treat (ITT) population belonged in PSI
Class V. However, since all of them were in the
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528 Patients Treated
Intent-to-Treat
Population (ITT)
256 Patients Received
Levofloxacin 750 mg,
5 days (ITT)
272 Patients Received
Levofloxacin 500 mg,
10 days (ITT)
ITT Patients in PSI ITT Patients in PSI
Levofloxacin for severe CAP 2131500-mg treatment group, these patients were
not included in this analysis. Clinical signs and
symptoms were reassessed for each group during an
on-therapy visit (day 3), the posttherapy visits
(7–14 days after study entry), and a poststudy visit
(31–38 days after study entry). The protocol was
approved by the participating institutions’ institu-
tional review boards; written informed consent was
obtained before initiation of study procedures.Class III/IV
61 Patients in PSI III 
40 Patients in PSI IV
Class III/IV
68 Patients in PSI III
50 Patients in PSI IV
Clinically-evaluable
Patients in PSI
Class III/IV
51 Patients in PSI III
32 Patients in PSI IV
Clinically-evaluable
Patients in PSI
Class III/IV
49 Patients in PSI III
27 Patients in PSI IV
Microbiologically-
evaluable Patients in
PSI Class III/IV
27 Patients in PSI III
9 Patients in PSI IV
Microbiologically-
evaluable Patients in
PSI Class III/IV
17 Patients in PSI III
15 Patients in PSI IV
Figure 1 Patient populations.Statistical analysis
A two-sided 95% CI with continuity correction was
calculated around the difference of clinical success
rates of the two treatment groups (levofloxacin
500-mg, 10-day regimen minus levofloxacin 750-
mg, 5-day regimen). The change in the percentage
of patients reporting the symptom between admis-
sion and day 3 for the 750- and 500-mg treated
patients was compared using a two-sample McNe-
mar’s test, as previously reported.16 For adverse
events, a P-value was computed with a w2 test to
determine the significance of the difference in the
number of patients with treatment-emergent ad-
verse events between the treatment groups.Results
Patient demographics and baseline
characteristics
The distribution of patient populations is illustrated
in Fig. 1. Of the 528 patients in the intent-to-treat
(ITT) population for the study, 219 (41.5%) patients
belonged to PSI Class III or IV, with 101 patients
treated with 750-mg levofloxacin and 118 patients
treated with 500-mg levofloxacin. Baseline demo-
graphics of the ITT and clinically evaluable (CE)
populations were comparable between treatment
groups, including the presence of comorbidities.
The mean age was 66.0711.6 in the 750-mg
group, compared to 68.2712.0 in the 500-mg
group. (This compares to a mean age in the overall
study of 53.1 and 55.3 for the 750- and 500-mg
groups, respectively.) The mean overall PSI scores
for the CE population were 87.6 for the 750-mg
group and 88.6 for the 500-mg group. For patients
belonging to PSI Class III, the mean scores were
78.7 and 79.1 for the 750- and 500-mg groups,
respectively. Among patients in PSI Class IV, the
mean scores were 103.7 and 103.8 for those
treated with 750- and 500-mg levofloxacin, respec-
tively.Clinical success and microbiologic
eradication rates
The clinical success rates for patients belonging to
PSI Class III/IV are shown in Table 1. As reported
earlier, the overall cure rates were lower in these
patients than in the less severely ill CAP patients
(PSI Class I/II) (88.1% for PSI Class III/IV vs 94.7% for
PSI Class I/II, both treatment groups combined).17
Overall, both treatment regimens achieved com-
parable clinical success rates, though the 750-mg
regimen resulted in slightly higher rates overall
(90.8% vs 85.5%; 95% CI, 15.9 to 5.4), and for both
PSI Class III and IV patients assessed individually.
Both treatment regimens also resulted in compar-
able microbiologic eradication rates in the overall
ME population (88.9% for the 750-mg group, and
87.5% for the 500-mg group; 95% CI, 18.3 to 15.6).
When patients were analyzed according to the
primary pathogen of interest, both levofloxacin
regimens showed comparable effectiveness against
each of the most common pathogens identified
(Table 2).Patients with bacteremia
Positive blood cultures were obtained from 9
microbiologically evaluable patients in this study,
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Table 1 Clinical success rates for the clinically evaluable population at posttherapy, based on PSI score.
n/N (%) of Patients 95% CIy
750mg 500mg
PSI classes III and IV 69/76 (90.8) 71/83 (85.5) 15.9 to 5.4
PSI classes III only 44/49 (89.8) 44/51 (86.3) 17.2 to 10.2
PSI classes IV only 25/27 (92.6) 27/32 (84.4) 26.1 to 9.6
Clinical success includes cured and improved.
yTwo-sided 95% CI with continuity correction were calculated around the difference (levofloxacin 500-mg/10-day regimen
minus levofloxacin 750-mg/5-day regimen).
Table 2 Microbiologic eradication rates at posttherapy by pathogen of primary interest identified in PSI Class
III/IV microbiologically evaluable patients.
n/N (%) of Patients 95% CIy
750mg (N ¼ 36) 500mg (N ¼ 32)
Total patients 32/36 (88.9) 28/32 (87.5) 18.3 to 15.6
Respiratory cultures (typical pathogens)
H. influenzae 6/7 (85.7) 4/5 (80.0)
H. parainfluenzae 3/3 (100) 4/5 (80.0)
S. pneumoniae 6/7 (85.7) 6/8 (75.0)
Serologies (atypical pathogens)
C. pneumoniae 5/6 (83.3) 4/4 (100)
L. pneumophila 4/4 (100) 2/2 (100)
M. pneumoniae 9/10 (90.0) 10/11 (90.9)
Eradication rates include eradicated and presumed eradicated.
yTwo-sided 95% CI with continuity correction was calculated around the difference (levofloxacin 500-mg/10-day regimen
minus levofloxacin 750-mg/5-day regimen).
A.F. Shorr et al.2132regardless of PSI class (5 patients treated with 750-
mg levofloxacin and 4 patients treated with the
500-mg dose). In the 750-mg treatment group, 3
were identified with Escherichia coli (all of which
were eradicated with treatment) and 2 were
infected with S. pneumoniae (both of whom were
presumed persisted after treatment although no
blood cultures were done to confirm this). All 4
bacteremic patients in the 500-mg group were
identified with S. pneumoniae infections. Three
patients had the infection eradicated after treat-
ment while one patient’s infection (S. pneumoniae)
persisted at the posttherapy evaluation. The
patient withdrew from study medication after
taking 3 doses of 500mg levofloxacin and was
hospitalized for 11 days and received piperacillin/
tazobactam (4.5 g IV) and levofloxacin (500mg IV).
The levofloxacin MIC of this isolate remained
unchanged at 1 mg/mL. Isolates were unavailable
from the two patients in the 750-mg group that
failed therapy.Safety
The overall safety profiles of the 750- and 500-mg
levofloxacin regimens are shown in Table 3 for the ITT
population. Overall, 62.4% of patients receiving the
750-mg regimen experienced at least 1 treatment-
emergent adverse event, compared with 69.0% of
patients receiving the 500-mg dose (P ¼.307). The
percentages of patients experiencing adverse events
considered to be drug-related were also similar
(19.8% for the 750-mg group compared to 19.8% for
the 500-mg group; P ¼.996), suggesting the higher
dose of levofloxacin was as well tolerated as the 500-
mg dose in these patients. The most common
treatment-emergent adverse events for the 750-
and 500-mg treatment groups, respectively, were
insomnia (3.0% and 8.6%), peripheral edema (3.0%
and 4.3%), nausea (4.0% and 2.6%), constipation (4.0%
and 1.7%) and pain (1.0% and 4.3%) (Table 4). The
overall rates of adverse events were not significantly
different between the treatment groups.
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Table 3 Overall safety results (PSI classes III and IV intent-to-treat patients).
n/N (%) of Patients P-valuey
750-mg (N ¼ 101) 500-mg (N ¼ 116)
Patients with X1 treatment-emergent AE 63 (62.4) 80 (69.0) .307
Patients with X1 treatment-related AE 20 (19.8) 23 (19.8) .996
Patients with X1 serious AE 13 (12.9) 22 (19.0) .223
Discontinuation due to AEs 7 (6.9) 12 (10.3) .375
Deathsz 3 (3.0) 6 (5.2) .508y
Two patients were excluded from the safety analysis due to lack of postadmission safety data.
yP-values determined by w2 test unless otherwise noted.
zNone of the deaths in either treatment group were assessed as related to study drug.
yP-value determined by Fischer’s exact test.
Table 4 Incidence of treatment-emergent AEs (X2% of either treatment group).
Adverse event by body system 750-mg (N ¼ 101) n (%) 500-mg (N ¼ 116) n (%)
Any adverse event 63 (62.4) 80 (69.0)
Body as a whole
Edema, peripheral 3 (3.0) 5 (4.3)
Condition aggravated 2 (2.0) 3 (2.6)
Pain 1 (1.0) 5 (4.3)
Cardiovascular
Hypotension 3 (3.0) 2 (1.7)
CNS
Headache 3 (3.0) 2 (1.7)
Dizziness 2 (2.0) 0 (.0)
Gastrointestinal
Constipation 4 (4.0) 2 (1.7)
Nausea 4 (4.0) 3 (2.6)
Vomiting 3 (3.0) 0 (.0)
Diarrhea 1 (1.0) 4 (3.4)
Metabolic and nutritional
Hypokalemia 3 (3.0) 2 (1.7)
Myocardial disorder
Myocardial infarction 2 (2.0) 0 (.0)
Platelet, bleeding and clotting
Epistaxis 2 (2.0) 0 (.0)
Psychiatric
Insomnia 3 (3.0) 10 (8.6)
Respiratory system
Chronic obstructive airways disease 4 (4.0) 0 (.0)
Skin
Rash 1 (1.0) 3 (2.6)
Rash erythematous 0 (.0) 4 (3.4)
Levofloxacin for severe CAP 2133Resolution of CAP symptoms
Previous analyses have indicated that, though
clinical and microbiologic results were comparable
between the 750- and 500-mg levofloxacin regi-mens, there were differences in the proportion of
patients experiencing symptom resolution between
admission and day 3 of treatment. Symptom
resolution results for patients in PSI Class III and
IV (ITT population) are shown in Table 5. A
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Table 5 Resolution of CAP symptoms by day 3 of therapy (PSI classes III and IV intent-to-treat patients).
n/N (%) of Patients P-valuey
750-mg 500-mg
Purulent sputum 46/95 (48.4) 30/109 (27.5) .007
Fever (patient reported) 63/95 (66.3) 52/109 (47.7) .008
Fever (measured) 44/91 (48.4) 36/106 (34.0) .046
Pleuritic chest pain 34/95 (35.8) 28/109 (25.7) .135
Shortness of breath 31/95 (32.6) 29/109 (26.6) .419
Chills 51/95 (53.7) 54/109 (49.5) .571
Cough 15/95 (15.8) 15/109 (13.8) .736
Total number of patients assessed who had a response documented at both baseline and Day 3. For each symptom analysed,
n ¼ (# patients reporting ‘‘yes’’ at baseline and ‘‘no’’ at Day 3)(# patients reporting ‘‘no’’ at baseline and ‘‘yes’’ at Day 3).
yP-value was computed from a two-sample McNemar’s test.
A.F. Shorr et al.2134significantly greater proportion of patients receiv-
ing the 750-mg regimen experienced resolution of
fever (patient-reported fever, 66.3% vs 47.7%,
P ¼.008; measured fever, 48.4% vs 34.0%,
P ¼.046) and purulent sputum (48.4% vs 27.5%;
P ¼.007) by day 3 of therapy compared to the 500-
mg treatment group. No significant differences
were observed between the two groups for other
symptoms assessed at day 3 (shortness of breath,
chills, cough, and pleuritic chest pain).Discussion
This subgroup analysis of a prospective, rando-
mized, double-blind, active treatment-controlled,
noninferiority study showed that a 750-mg, 5-day
levofloxacin regimen achieved comparable clinical
and microbiological results to the 500-mg, 10-day
course for hospitalized PSI III/IV CAP patients. In
the overall clinically evaluable population, the 750-
mg course achieved over 90% success rate, while
both regimens were effective against a variety of
pathogens identified in the microbiologically evalu-
able population. Importantly, the higher dose of
levofloxacin was as well tolerated as the 500-mg
dose.
The safety of fluoroquinolones has garnered
much attention recently, in particular with regards
to cardiovascular effects and glucose homeosta-
sis.20–24 This can be of particular importance with
the more severely ill population as these patients
may present with comorbidities and have hepatic
or renal dysfunction, thereby affecting normal
elimination of the agent. In particular, one study
has indicated a dose-dependent effect of fluoro-
quinolones on QTc interval prolongation in healthy
adults.25 The higher dose of levofloxacin in thepresent clinical study did not reveal a higher
incidence of treatment-emergent or serious ad-
verse events compared to the 500-mg dose.
A greater proportion of patients receiving 750-
mg levofloxacin experienced resolution of fever
and purulent sputum by day 3 of therapy. This can
be particularly important in the hospital setting, as
clinical stability is commonly used as one of the
criteria to determine switch from IV to oral
therapy.4,26–28 An earlier switch to oral medication
can provide numerous clinical and economic ben-
efits, including improved patient comfort, reduced
nosocomial acquisition rates, and a reduced risk for
adverse events associated with IV medications
(such as injection site reactions and line sepsis).
In a time of increasing pressure for cost efficiency
at hospitals, a more rapid switch to oral medication
will lower overall drug costs and reduce the time
and resources required for drug preparation and
administration by healthcare personnel. Reducing
the time to switch may also lead to an earlier
hospital discharge as illustrated in several studies
from hospitals that have utilized automatic IV-to-
oral switch programs.4,26,29,30 In the overall patient
population of this study, the general trend revealed
more rapid IV-to-oral switch for the 750-mg group
compared to the 500-mg group, though the
difference was not significant.18 Approximately
70% of PSI III/IV patients in this study were initially
treated with IV dosing. Unfortunately, specific
protocols for determining the time to switch were
not instituted. Therefore, interpreting any results
in switch time would be difficult given the hetero-
geneity in prescribing across the multiple centres
included in the trial.
The main limitations of this analysis relate to its
being a post hoc subgroup analysis of a prospective
study. Some data that may have been pertinent to
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Levofloxacin for severe CAP 2135include in this report were not collected, such as
length of hospital stay, which may have provided
some insight on the pharmacoeconomic implica-
tions of the 750-mg, short-course regimen. A
specific protocol was not provided to investigators
for determining the time of IV-to-oral switch. The
number of bacteremia patients was low, as were
the number of PSI Class V patients, so definitive
conclusions regarding the 750-mg, 5-day levoflox-
acin regimen cannot be appropriately transferred
to these patient populations. However, one report
documented the efficacy of 500- or 750-mg levo-
floxacin in 108 cases of pneumococcal bacteremia,
with a clinical success rate over 90%, suggesting
this agent is highly effective against these types of
infections.31 Finally, this study did not investigate
the emergence of resistance following antibacterial
treatment.
It is important to note that this study introduces
two variables in the study design, dosing and
duration, so that it is difficult to directly compare
the efficacy of 750- and 500-mg levofloxacin dosing.
Therefore, hypothetically, a 500-mg, 5-day levo-
floxacin regimen may be comparable to the 750-mg
regimen. The 750-mg dose, however, does suggest
more rapid resolution of CAP symptoms, as these
were measured by day 3 of therapy. The higher
dose may also reduce the risk of resistance
development and be effective against less suscep-
tible pathogens, though further studies are needed
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